







an Open Access Journal by MDPI

# **Infectious Diseases, Epidemiology and Vaccination**

Guest Editors:

### Dr. Catalina Ciocan

Department of Public Health and Pediatrics, University of Torino, 10124 Torino, Italy

### Dr. Alessandro Godono

Department of Public Health and Pediatrics, University of Torino, 10124 Torino, Italy

#### Dr. Marco Clari

Department of Public Health and Pediatrics, University of Torino, 10124 Torino, Italy

Deadline for manuscript submissions:

closed (31 March 2024)

# **Message from the Guest Editors**

Dear colleagues,

We strongly believe that this model could be successfully replicated for many infectious diseases, and we emphasize the importance of the multidisciplinary and strategic collaborative effort in hazard identification; in the application of prevention and control measures in both occupational and public health settings; and in the control of appropriate use of antibiotics, screening, and active surveillance of infected subjects.

Therefore, authors are invited to submit their latest research regarding emerging infectious agents and the latest developments in vaccines, vaccine technology, and vaccination practices. Additionally, we would like to dedicate a section of this Special Issue to hospital infections and major infective agents regarding healthcare workers.







IMPACT FACTOR 7.8





an Open Access Journal by MDPI

## **Editor-in-Chief**

### Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

## **Message from the Editor-in-Chief**

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

### **Author Benefits**

**Open Access:** free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## **Contact Us**